Human pancreatic cancer fusion 2 (HPC2) 1-B3: A novel monoclonal antibody to screen for pancreatic ductal dysplasia

Terry Morgan, Karin Hardiman, Christopher Corless, Sandra L. White, Robert Bonnah, Henry Van De Vrugt, Brett Sheppard, Markus Grompe, Ediz F. Cosar, Philip Streeter

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND. Pancreatic ductal adenocarcinoma is rarely detected early enough for patients to be cured. The objective of the authors was to develop a monoclonal antibody to distinguish adenocarcinoma and precancerous intraductal papillary mucinous neoplasia (IPMN) from benign epithelium. METHODS. Mice were immunized with human pancreatic adenocarcinoma cells and monoclonal antibodies were screened against a panel of archived pancreatic tissue sections, including pancreatitis (23 cases), grade 1 IPMN (16 cases), grade 2 IPMN (9 cases), grade 3 IPMN (13 cases), and various grades of adenocarcinoma (17 cases). One monoclonal antibody, human pancreatic cancer fusion 2 (HPC2) 1-B3, which specifically immunostained adenocarcinoma and all grades of IPMN, was isolated. Subsequently, HPC2 1-B3 was evaluated in a retrospective series of 31 fine-needle aspiration (FNA) biopsies from clinically suspicious pancreatic lesions that had long-term clinical follow-up. RESULTS. HPC2 1-B3 was negative in all 31 cases of chronic pancreatitis that were tested. In contrast, HPC2 1-B3 immunostained the cytoplasm and luminal surface of all 16 well- to moderately differentiated pancreatic ductal adenocarcinomas. It demonstrated only weak focal staining of poorly differentiated carcinomas. All high-grade IPMNs were found to be positive for HPC2 1-B3. The majority of low-grade to intermediate-grade IPMNs were positive (66% of cases). Immunostaining a separate series of pancreatic FNA cell blocks for HPC2 1-B3 demonstrated that the relative risk for detecting at least low-grade dysplasia (2.0 [95% confidence interval, 1.23-3.26]) was statistically significant (P = .002 by the Fisher exact test). CONCLUSIONS. To reduce the mortality of pancreatic cancer, more effective early screening methods are necessary. The data from the current study indicate that a novel monoclonal antibody, HPC2 1-B3, may facilitate the diagnosis of early pancreatic dysplasia.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalCancer cytopathology
Volume121
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Pancreatic Neoplasms
Monoclonal Antibodies
Adenocarcinoma
Neoplasms
Fine Needle Biopsy
Chronic Pancreatitis
Pancreatitis
Cytoplasm
Epithelium
Confidence Intervals
Staining and Labeling
Carcinoma
Mortality

Keywords

  • Ductal adenocarcinoma
  • Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA)
  • Intraductal papillary mucinous neoplasm (IPMN)
  • Monoclonal antibody
  • Pancreas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Human pancreatic cancer fusion 2 (HPC2) 1-B3 : A novel monoclonal antibody to screen for pancreatic ductal dysplasia. / Morgan, Terry; Hardiman, Karin; Corless, Christopher; White, Sandra L.; Bonnah, Robert; Van De Vrugt, Henry; Sheppard, Brett; Grompe, Markus; Cosar, Ediz F.; Streeter, Philip.

In: Cancer cytopathology, Vol. 121, No. 1, 01.2013, p. 37-46.

Research output: Contribution to journalArticle

Morgan, Terry ; Hardiman, Karin ; Corless, Christopher ; White, Sandra L. ; Bonnah, Robert ; Van De Vrugt, Henry ; Sheppard, Brett ; Grompe, Markus ; Cosar, Ediz F. ; Streeter, Philip. / Human pancreatic cancer fusion 2 (HPC2) 1-B3 : A novel monoclonal antibody to screen for pancreatic ductal dysplasia. In: Cancer cytopathology. 2013 ; Vol. 121, No. 1. pp. 37-46.
@article{4948c3c2e7b64f65905f18b2bffa8554,
title = "Human pancreatic cancer fusion 2 (HPC2) 1-B3: A novel monoclonal antibody to screen for pancreatic ductal dysplasia",
abstract = "BACKGROUND. Pancreatic ductal adenocarcinoma is rarely detected early enough for patients to be cured. The objective of the authors was to develop a monoclonal antibody to distinguish adenocarcinoma and precancerous intraductal papillary mucinous neoplasia (IPMN) from benign epithelium. METHODS. Mice were immunized with human pancreatic adenocarcinoma cells and monoclonal antibodies were screened against a panel of archived pancreatic tissue sections, including pancreatitis (23 cases), grade 1 IPMN (16 cases), grade 2 IPMN (9 cases), grade 3 IPMN (13 cases), and various grades of adenocarcinoma (17 cases). One monoclonal antibody, human pancreatic cancer fusion 2 (HPC2) 1-B3, which specifically immunostained adenocarcinoma and all grades of IPMN, was isolated. Subsequently, HPC2 1-B3 was evaluated in a retrospective series of 31 fine-needle aspiration (FNA) biopsies from clinically suspicious pancreatic lesions that had long-term clinical follow-up. RESULTS. HPC2 1-B3 was negative in all 31 cases of chronic pancreatitis that were tested. In contrast, HPC2 1-B3 immunostained the cytoplasm and luminal surface of all 16 well- to moderately differentiated pancreatic ductal adenocarcinomas. It demonstrated only weak focal staining of poorly differentiated carcinomas. All high-grade IPMNs were found to be positive for HPC2 1-B3. The majority of low-grade to intermediate-grade IPMNs were positive (66{\%} of cases). Immunostaining a separate series of pancreatic FNA cell blocks for HPC2 1-B3 demonstrated that the relative risk for detecting at least low-grade dysplasia (2.0 [95{\%} confidence interval, 1.23-3.26]) was statistically significant (P = .002 by the Fisher exact test). CONCLUSIONS. To reduce the mortality of pancreatic cancer, more effective early screening methods are necessary. The data from the current study indicate that a novel monoclonal antibody, HPC2 1-B3, may facilitate the diagnosis of early pancreatic dysplasia.",
keywords = "Ductal adenocarcinoma, Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA), Intraductal papillary mucinous neoplasm (IPMN), Monoclonal antibody, Pancreas",
author = "Terry Morgan and Karin Hardiman and Christopher Corless and White, {Sandra L.} and Robert Bonnah and {Van De Vrugt}, Henry and Brett Sheppard and Markus Grompe and Cosar, {Ediz F.} and Philip Streeter",
year = "2013",
month = "1",
doi = "10.1002/cncy.21223",
language = "English (US)",
volume = "121",
pages = "37--46",
journal = "Cancer cytopathology",
issn = "1934-662X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Human pancreatic cancer fusion 2 (HPC2) 1-B3

T2 - A novel monoclonal antibody to screen for pancreatic ductal dysplasia

AU - Morgan, Terry

AU - Hardiman, Karin

AU - Corless, Christopher

AU - White, Sandra L.

AU - Bonnah, Robert

AU - Van De Vrugt, Henry

AU - Sheppard, Brett

AU - Grompe, Markus

AU - Cosar, Ediz F.

AU - Streeter, Philip

PY - 2013/1

Y1 - 2013/1

N2 - BACKGROUND. Pancreatic ductal adenocarcinoma is rarely detected early enough for patients to be cured. The objective of the authors was to develop a monoclonal antibody to distinguish adenocarcinoma and precancerous intraductal papillary mucinous neoplasia (IPMN) from benign epithelium. METHODS. Mice were immunized with human pancreatic adenocarcinoma cells and monoclonal antibodies were screened against a panel of archived pancreatic tissue sections, including pancreatitis (23 cases), grade 1 IPMN (16 cases), grade 2 IPMN (9 cases), grade 3 IPMN (13 cases), and various grades of adenocarcinoma (17 cases). One monoclonal antibody, human pancreatic cancer fusion 2 (HPC2) 1-B3, which specifically immunostained adenocarcinoma and all grades of IPMN, was isolated. Subsequently, HPC2 1-B3 was evaluated in a retrospective series of 31 fine-needle aspiration (FNA) biopsies from clinically suspicious pancreatic lesions that had long-term clinical follow-up. RESULTS. HPC2 1-B3 was negative in all 31 cases of chronic pancreatitis that were tested. In contrast, HPC2 1-B3 immunostained the cytoplasm and luminal surface of all 16 well- to moderately differentiated pancreatic ductal adenocarcinomas. It demonstrated only weak focal staining of poorly differentiated carcinomas. All high-grade IPMNs were found to be positive for HPC2 1-B3. The majority of low-grade to intermediate-grade IPMNs were positive (66% of cases). Immunostaining a separate series of pancreatic FNA cell blocks for HPC2 1-B3 demonstrated that the relative risk for detecting at least low-grade dysplasia (2.0 [95% confidence interval, 1.23-3.26]) was statistically significant (P = .002 by the Fisher exact test). CONCLUSIONS. To reduce the mortality of pancreatic cancer, more effective early screening methods are necessary. The data from the current study indicate that a novel monoclonal antibody, HPC2 1-B3, may facilitate the diagnosis of early pancreatic dysplasia.

AB - BACKGROUND. Pancreatic ductal adenocarcinoma is rarely detected early enough for patients to be cured. The objective of the authors was to develop a monoclonal antibody to distinguish adenocarcinoma and precancerous intraductal papillary mucinous neoplasia (IPMN) from benign epithelium. METHODS. Mice were immunized with human pancreatic adenocarcinoma cells and monoclonal antibodies were screened against a panel of archived pancreatic tissue sections, including pancreatitis (23 cases), grade 1 IPMN (16 cases), grade 2 IPMN (9 cases), grade 3 IPMN (13 cases), and various grades of adenocarcinoma (17 cases). One monoclonal antibody, human pancreatic cancer fusion 2 (HPC2) 1-B3, which specifically immunostained adenocarcinoma and all grades of IPMN, was isolated. Subsequently, HPC2 1-B3 was evaluated in a retrospective series of 31 fine-needle aspiration (FNA) biopsies from clinically suspicious pancreatic lesions that had long-term clinical follow-up. RESULTS. HPC2 1-B3 was negative in all 31 cases of chronic pancreatitis that were tested. In contrast, HPC2 1-B3 immunostained the cytoplasm and luminal surface of all 16 well- to moderately differentiated pancreatic ductal adenocarcinomas. It demonstrated only weak focal staining of poorly differentiated carcinomas. All high-grade IPMNs were found to be positive for HPC2 1-B3. The majority of low-grade to intermediate-grade IPMNs were positive (66% of cases). Immunostaining a separate series of pancreatic FNA cell blocks for HPC2 1-B3 demonstrated that the relative risk for detecting at least low-grade dysplasia (2.0 [95% confidence interval, 1.23-3.26]) was statistically significant (P = .002 by the Fisher exact test). CONCLUSIONS. To reduce the mortality of pancreatic cancer, more effective early screening methods are necessary. The data from the current study indicate that a novel monoclonal antibody, HPC2 1-B3, may facilitate the diagnosis of early pancreatic dysplasia.

KW - Ductal adenocarcinoma

KW - Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA)

KW - Intraductal papillary mucinous neoplasm (IPMN)

KW - Monoclonal antibody

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=84874674363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874674363&partnerID=8YFLogxK

U2 - 10.1002/cncy.21223

DO - 10.1002/cncy.21223

M3 - Article

C2 - 22811080

AN - SCOPUS:84874674363

VL - 121

SP - 37

EP - 46

JO - Cancer cytopathology

JF - Cancer cytopathology

SN - 1934-662X

IS - 1

ER -